Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Nutraceutical
- Healthcare
- Supplements
- Therapeutic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26256
License Grant
The Company entered into a license agreement with University that grants the Company an exclusive, worldwide license to (1) the PharmaPrint Process; (2) use certain therapeutic compounds; and (3) other related products developed by Dr. Khwaja's laboratory at USC. USC has also agreed to grant the Company the right to sublicense certain products and a right of first refusal to obtain a license for any improvements to certain products developed by USC. The term of the USC License Agreement began March 1, 1995, and ends on the later of February 28, 2010, or the expiration of the last issued patent under the USC License Agreement.
License Property
PharmaPrint Process technology develops pharmaceutical-grade dietary supplement products and pharmaceuticals from botanical sources. Unlike the traditional drug development process of identifying and synthesizing single bioactive molecules from plant sources, the Company's core technologies were developed based on empirical data that suggests that the health benefits and safe usage of certain plant-derived therapeutics might be the result of the natural combination of multiple molecules found in the plant extract and that single molecules, in isolation, may not replicate the natural plants' effectiveness. The PharmaPrint Process technology enables the Company to identify and quantify the bioactives within plant sources that are believed to provide therapeutic benefits and produce dietary supplements and pharmaceuticals having consistent batch-to-batch quantities and ratios of these bioactives.
IPSCIO Record ID: 173732
License Grant
University and Licensee wish to amend the License Agreement. This amendment modifies terms of the agreement including the royalty.
License Property
The agreement includes Products which are Pharmaceuticals (Rx), Over-The-Counter (OTC), and Dietary Supplement Health and Education Act (DSHEA) extracts or compounds.
Unlike the traditional drug development process of identifying and synthesizing single bioactive molecules from plant sources, the Company's core technologies were developed based on empirical data that suggests that the health benefits and safe usage of certain plant-derived therapeutics might be the result of the natural combination of multiple molecules found in the plant extract and that single molecules, in isolation, may not replicate the natural plants' effectiveness. The PharmaPrint Process technology enables the Company to identify and quantify the bioactives within plant sources that are believed to provide therapeutic benefits and produce dietary supplements and pharmaceuticals having consistent batch-to-batch quantities and ratios of these bioactives.
Field of Use
This agreement is for the pharmaceutical and dietary health care industry.
IPSCIO Record ID: 28225
License Grant
Party A hereby assigns, transfers and sets over to Party B all right, title and interest to all patents, registrations and/or applications filed by Party A or its agent in any jurisdiction in the Asia Pacific Region. Party A hereby grants Party B a non-exclusive, perpetual, royalty- free (except pursuant to royalty consideration) and fully-paid license (i) to use, modify, reproduce, display, make, deploy and otherwise exploit the Patented Technology, Know-How and the associated intellectual property rights therein in the manufacturing of the Products, and (ii) to sublicense any of the foregoing rights in any jurisdiction in the Asia Pacific Region (collectively, the Technology License), each during the term of this Agreement. Party A hereby grants Party B an exclusive, perpetual, royalty-free (except pursuant to royalty consideration) and fully-paid license (i) to use the Licensed Marks in the Asia Pacific Region and (ii) to sublicense any of the foregoing rights pursuant to Section 14 in any jurisdiction in the Asia Pacific Region (collectively, the Trademark License), each during the term of this Agreement. Party A hereby grants to Party B an exclusive and perpetual right and license to market, promote and distribute (the Distribution Right) the Product in the Asia Pacific Region on the terms and conditions set out below during the term of this Agreement.
License Property
Product means the dietary supplements, functional foods and pharmaceuticals derived from natural plant extracts produced by Party B or any sublicensee, contractor or other third party using the Patented Technology. The technology enables the precise identification and consistent replication of the active ingredients from the natural plant extracts that are scientifically believed to provide the desired health benefits.
Pharmaceutical Grade Botanical Drugs 04/15/97 28131/97 Issued
Pharmaceutical Grade Echinacea 10/23/98 13634/99 Pending
Pharmaceutical Grade Ginkgo Biloba 10/23/98 13633/99 Pending
Pharmaceutical Grade Ginseng 10/23/98 11183/99 Pending
Pharmaceutical Grade Saw Palmetto, 10/23/98 13635/99 Pending
Serenoa Repens
Pharmaceutical Grade St. John's Wort 10/23/98 13631/99 Pending
Pharmaceutical Grade Valerian, Black 10/23/98 13632/99 Pending
Cohosh, Vitex Agnus-Castus, Bilberry and Milk Thistle
Field of Use
This agreement pertains to the medical industry.
IPSCIO Record ID: 9475
License Grant
Licensor hereby grants to Licensee the sole and exclusive right, without the right to grant sublicenses except to Licensee's Affiliate(s), under the Patent Rights to market and sell Herbal Products, including the Licensed Products, in the OTC Market in the Territory.
Licensor hereby grants to Licensee a non-exclusive right, without the right to grant sublicenses except to Licensee's Affiliate(s), under the Patent Rights to use the Herbal Products, including the Licensed Products, in the OTC Market in the Territory.
License Property
Licensor has developed a method for the identification, characterization of and regulation of the amounts of bioactive components in herbal products and is seeking to commercialize certain of the herbal products identified, characterized and regulated thereby.
The Trademark shall mean the trademark PHARMAPRINT.
Herbal Product shall mean a dietary supplement derived from botanical herbal extracts.This agreement is for the dietary supplement industry.
The term 'Process Patent' shall mean U.S. Patent Application No. 08/838,199, filed April 15, 1997, a continuation-in-part application of U.S. Patent Application No. 08/632,273, filed April 15, 1996 or a patent issued on a divisional, continuation or continuation-in-part application on one or more of the patent applications for the Process Patent.
Field of Use
The rights granted apply to the vitamin market.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
